ArticleJournal of cachexia, sarcopenia and muscle2025
Small Extracellular Vesicles Derived From Damaged Muscle Aggravate Kidney Injury Progression.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.Renal failure · 2026Review
- Skeletal muscle‑derived extracellular vesicles in multi‑organ degenerative disease: Mechanisms and therapeutic delivery perspectives (Review).International journal of molecular medicine · 2026Review
- Effects of exercise‑derived extracellular vesicles: Epigenetic regulatory mechanisms and protective roles (Review).International journal of molecular medicine · 2026Review
- Extracellular vesicles derived from immobilization-induced atrophic muscle of male mice contain distinct microRNA profiles and impact mRNA profiles in brain neurons.Physiological reports · 2026Article
- Exercise rejuvenates the "muscle-heart" crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMuscle atrophy is commonly associated with kidney dysfunction in patients with renal disease. However, the effects of skeletal muscle loss per se on kidney function have not been fully elucidated. Here, we examined muscle-kidney crosstalk by evaluating the role of muscle-derived small extracellular vesicles (EVs) on the progression of kidney injury.
methodsA denervation-induced muscle loss model was established, and kidney inflammation and fibrosis were evaluated in unilateral ureteral obstruction (UUO)-induced kidney injury and adenine diet-induced chronic kidney disease models. Changes in small EV markers (CD9, CD63, CD81 and Alix) were measured. GW4869, an inhibitor of EV biogenesis and release, was used to confirm the role of denervated muscle-derived small EVs on the progression of kidney fibrosis. To obtain direct evidence on the crosstalk, EVs were isolated from plasma of denervated mice and conditioned media from differentiated myotubes and treated in vivo and in vitro. To determine the effect of exercise-induced EVs on kidney fibrosis, EVs isolated from exercised mice and trained humans were treated to TGFβ1-stimulated mProx24 renal tubular epithelial cells.
resultsDenervation aggravated kidney injury, as shown by a 10% increase in albuminuria and upregulation of inflammatory and fibrotic markers in the kidney. Significant interactions between denervation and UUO were observed for renal αSMA (F = 47.19, p < 0.0001) and FN (F = 19.06, p = 0.0001) expression. EV production and secretion were markedly increased in damaged muscle, both in vivo and in vitro. Pharmacological depletion of EVs using GW4869 via intraperitoneal and intramuscular injection reduced kidney injury by over 20%. Furthermore, injection of EVs from denervated muscle into UUO mice, as well as treatment of mProx24 cells with EVs from either denervated mice or damaged C2C12 myotubes, significantly amplified renal injury. Among the EV cargo, miR-21a-3p-identified as a regulator of Ppargc1a-was elevated over 10-fold in EVs from denervated muscle compared with sham controls. Importantly, EV-induced injury in mProx24 cells was reversed by pretreatment with a miR-21a inhibitor. In contrast, exercise downregulated miR-21a-3p expression in muscle, and EVs derived from exercised mice and humans attenuated kidney fibrosis.
conclusionsOur findings provide novel evidence that skeletal muscle loss can serve as an upstream contributor to kidney disease. Muscle-derived EVs from damaged tissue exacerbate, while those from exercised muscle ameliorate, kidney injury, partly through miR-21a-3p regulation. These results highlight the critical role of miRNAs within muscle-derived EVs in maintaining kidney homeostasis and suggest their potential as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.